NeuroFX
Changing Minds

ADHD MEDICATION · 4.12

ADHD Medication in Pregnancy and Breastfeeding: What the Evidence Says

ADHD medication in pregnancy and breastfeeding is a decision-support area. Every decision is individual, specialist-led, and shaped by the limited but real evidence available.

FOR
Adults planning a pregnancy, pregnant, or breastfeeding on ADHD medication

AUDIENCE AGE
18+

REVIEWED
17 May 2026

PART OF
The NeuroFX resource library

info@neurofx.co.uk · 0333 533 3303 · neurofx.co.uk

IN SUMMARY

ADHD Medication in Pregnancy and Breastfeeding: What the Evidence Says

Why this question is difficult

- **The evidence base for any medication in pregnancy is necessarily limited.** Randomised trials in pregnancy are rare for ethical reasons. What is known comes from observational cohorts, pregnancy registries and case series. Numbers exposed to ADHD medication in pregnancy are smaller than for many other medications.
- **Three UK sources guide the picture.** UKTIS (UK Teratology Information Service) and its patient-facing arm BUMPS. The BNF entries for each medication in pregnancy and lactation. MHRA Drug Safety Updates when significant signals emerge.
- **Untreated ADHD in pregnancy has its own implications.** ADHD does not pause during pregnancy. Significant symptoms can affect engagement with antenatal care, mental health stability, driving safety and the practical management of pregnancy and early parenting. That sits on one side of the conversation.

What the current evidence suggests

- **Methylphenidate has the largest pregnancy dataset.** Available data is described by UKTIS and the BNF as limited but without a clear signal of substantially increased major malformations across the published cohorts. Where medication in pregnancy is being considered, it is the more usually evidenced option.
- **Lisdexamfetamine and dexamfetamine have smaller datasets.** Manufacturer guidance recommends avoidance unless benefit outweighs risk. Specialist input is required.
- **Atomoxetine and guanfacine have limited pregnancy data.** Both have specialist-led benefit-risk decisions in the BNF. No absolute prohibitions; case-by-case decisions.
- **Breastfeeding decisions are separate from pregnancy decisions.** Methylphenidate passes into breast milk in small amounts; UKTIS and BNF advise specialist input rather than blanket avoidance. Amphetamines (lisdexamfetamine, dexamfetamine), atomoxetine and guanfacine have more cautious manufacturer guidance.
- **Do not stop medication abruptly without specialist input.** Sudden discontinuation is not dangerous but can produce a noticeable return of symptoms. A planned conversation is better than an accidental pause.

How we approach this with you

- **Early consultation as soon as pregnancy is planned or confirmed.** Sooner is better. The conversation covers your current medication, the available evidence, your symptom picture, and the practical implications across pregnancy and into breastfeeding.
- **Specialist input including UKTIS where warranted.** NeuroFX can consult UKTIS directly for tailored advice on the specific medication and clinical picture. The decision is yours and the specialist's together.
- **Liaison with your GP, midwife and obstetric team.** ADHD medication during pregnancy is a multi-team picture. We support that liaison so the medication plan is known across the team caring for you.

WHEN TO SPEAK TO A PROFESSIONAL

Speak to your specialist prescriber as soon as you are planning a pregnancy or have become pregnant while on ADHD medication. Speak to your GP, midwife or NHS 111 if you have any pregnancy concern alongside your ADHD treatment. Seek urgent help via 999, A&E or maternity assessment for any pregnancy emergency or acute mental health crisis.

SOURCES

UKTIS / BUMPS; BNF; NICE NG87; MHRA Drug Safety Update

NEXT STEPS

Speak to NeuroFX

Private ADHD and autism assessment for adults and children aged 6 and upwards. CQC-registered. Bedford Consulting Rooms, 4 Goldington Road, Bedford MK40 3NF.

neurofx.co.uk · info@neurofx.co.uk · 0333 533 3303